PRGOPERRIGO Co plc
Pharmaceutical Preparations
- Revenue
- $4.3B
- 2.8% YoY
- Operating margin
- -26.4%
- 1122% YoY
- EBITDA
- −$785M
- 279% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $2.9B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear67% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear22% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $4.1B | $4.5B | $4.7B | $4.4B | $4.3B | 2.8% |
| Operating income | $410M | $79M | $152M | $113M | −$1.1B | 1094% |
| Net income | −$69M | −$141M | −$13M | −$172M | −$1.4B | 730% |
| Operating cash flow | $156M | $307M | $406M | $363M | $239M | 34% |
| Capex | $152M | $96M | $102M | $118M | $93M | 21% |
| Stock-based comp | $60M | $55M | $69M | $64M | $55M | 15% |
| Buybacks | $0 | $0 | — | — | — | |
| Dividends | $130M | $142M | $150M | $153M | $159M | 4.5% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.